Coronavirus | Sputnik V to be available in Indian markets by next week
Sputnik V vaccine for COVID-19, developed by Russia’s Gamaleya National Center, will be available in Indian markets from early next week, stated NITI Aayog member Dr. V.K. Paul on Thursday at a press convention.
Local manufacturing would start in July, with Hyderabad-based Dr. Reddy’s Laboratories manufacturing the vaccine, he acknowledged.
Sputnik V was given emergency use authorisation (EUA) by the Drugs Controller General of India (DCGI) in April and was first authorized in Russia on August 11 final. With an efficacy of 91.6%, as printed in the Lancet medical journal, the vaccine has been cleared and authorized for mass use in greater than 50 international locations. The Russian Direct Investment Fund (RDIF) has signed a deal to produce 750 million doses of Sputnik V in India.
India had additionally invited Pfizer, Moderna and Johnson and Johnson to manufacture in India and work with Indian corporations, Dr. Paul added.